Seres Therapeutics
NASDAQ: MCRBCambridge, US · Founded 2010 · 109 employees on LinkedIn · 4 known investors
Find your way into Seres Therapeutics
2,115 people in our graph share verified history with the Seres Therapeutics team — schools, employers, funds. One of them is your warm intro.
Yaryna Nychunlockedknows Matthew Henn · together at Harvard University (overlapped)
knows the team · via Flagship Pioneering
×3knows the team · via Broad Institute of MIT and Harvard
×5knows the team · via Harvard University
×2knows the team · via University of California, Berkeley
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome. The company pioneered the development and FDA approval of VOWST, an oral live biotherapeutic.
Founders & leadership
MH
Matthew HenninPresident and Chief Scientific OfficerMatthew Henn is President and Chief Scientific Officer at Seres Therapeutics, a clinical-stage biotechnology company developing live bacterial therapies to modulate the human microbiome. He has spent two decades in microbial ecology, microbiology, genomics, and bioinformatics, publishing over 70 peer-reviewed papers in environmental and human disease applications.
JA
John AuninsinSenior Advisor2020–2023
ED
Eric D. ShaffinPresident, Chief Executive Officer2019–2025
DC
David CookinEVP of R&D and Chief Scientific Officer2012–2019David Cook is an executive at Seres Therapeutics with experience spanning microbiome therapeutics, vaccines, biologics, and small molecules, and has overseen product development from discovery through regulatory approval, including obtaining EU marketing authorization for multiple medical products.
RJ
Roger J. PomerantzinSenior Clinical Advisor to the Board of DirectorsRoger J. Pomerantz led the development of 14 approved drugs across infectious diseases and microbiome therapeutics at Tibotec, Johnson & Johnson, and Merck, including HIV, HCV, TB, and CMV treatments, and served as a long-time member and chairman of the FDA's Antiviral Advisory Committee. He previously held academic positions with continuous NIH funding and is currently an executive officer and director at Seres Therapeutics.
RN
Richard N. KenderExecutive Chair and Interim Chief Executive Officer
Board
DB
NA
GB
Greg BeharBoard director
PB
Peter Barton HuttBoard director
WC
Werner CautreelsBoard director
LK
Lorence KimBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$123.6M disclosed across 3 of 7 rounds · 1900–2014
▶$65MraisedJan 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$65MraisedJan 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter Barton HuttDirector
- Richard KenderDirector
- David BerryDirector
- Werner CautreelsDirector
- Noubar AfeyanDirector
- John AuninsExecutive Officer
- Eric D. ShaffExecutive Officer
- David CookExecutive Officer
- Lorence KimDirector
- Greg BeharDirector
- Roger J. PomerantzExecutive Officer, Director
- Offering amount
- $65M
- Amount sold
- $65M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
▶$48MraisedDec 2014 · 20 investors · PharmaceuticalsRule 506(b)
▶$48MraisedDec 2014 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David BerryDirector
- Richard KenderDirector
- Werner CautreelsDirector
- Roger J. PomerantzExecutive Officer, Director
- John AuninsExecutive Officer
- Eric D. ShaffExecutive Officer
- Lorence KimDirector
- Noubar AfeyanDirector
- Peter Barton HuttDirector
- David CookExecutive Officer
- Offering amount
- $48M
- Amount sold
- $48M
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
▶$10.6MraisedJun 2014 · 10 investors · PharmaceuticalsRule 506(b)
▶$10.6MraisedJun 2014 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Werner CautreelsDirector
- David BerryDirector
- Noubar AfeyanDirector
- Roger PomerantzExecutive Officer, Director
- Peter Barton HuttDirector
- Offering amount
- $10.6M
- Amount sold
- $10.6M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$547.3Mvaluation at IPOJun 2015 · $18.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Seres Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlap
Robinhood25 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Sarepta Therapeutics24 shared keywordsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
Companies competing with Seres Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Seres Therapeutics do?
- Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome. The company pioneered the development and FDA approval of VOWST, an oral live biotherapeutic.
- Who are Seres Therapeutics's investors?
- Seres Therapeutics's investors include Flagship Pioneering, RA Capital, Sofinnova Ventures, Fidelity Investments.
- How much funding has Seres Therapeutics raised?
- Seres Therapeutics has disclosed $123.6M raised across 3 of its 7 known rounds.
- Where is Seres Therapeutics headquartered?
- Seres Therapeutics is headquartered in Cambridge, US.